Merck & Co., Inc. $MRK Shares Acquired by Triglav Investments D.O.O.

Triglav Investments D.O.O. increased its stake in Merck & Co., Inc. (NYSE:MRK) by 2.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 87,718 shares of the company’s stock after buying an additional 2,410 shares during the quarter. Triglav Investments D.O.O.’s holdings in Merck & Co., Inc. were worth $6,941,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of MRK. Charles Schwab Investment Management Inc. grew its stake in Merck & Co., Inc. by 144.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company’s stock valued at $4,418,820,000 after purchasing an additional 29,104,112 shares in the last quarter. Nuveen LLC acquired a new stake in Merck & Co., Inc. during the 1st quarter valued at approximately $991,553,000. Pacer Advisors Inc. grew its stake in Merck & Co., Inc. by 2,240.9% during the 1st quarter. Pacer Advisors Inc. now owns 5,286,801 shares of the company’s stock valued at $474,543,000 after purchasing an additional 5,060,959 shares in the last quarter. Amundi grew its stake in Merck & Co., Inc. by 37.1% during the 1st quarter. Amundi now owns 13,077,716 shares of the company’s stock valued at $1,130,397,000 after purchasing an additional 3,542,036 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in Merck & Co., Inc. during the 2nd quarter valued at approximately $258,267,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Down 0.2%

Shares of Merck & Co., Inc. stock opened at $86.15 on Friday. The business’s fifty day moving average price is $84.57 and its two-hundred day moving average price is $81.82. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The company has a market capitalization of $215.17 billion, a P/E ratio of 13.27, a PEG ratio of 0.95 and a beta of 0.37. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $105.07.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, October 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.22. The firm had revenue of $17.28 billion for the quarter, compared to the consensus estimate of $17 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The firm’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.57 EPS. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Wall Street Analyst Weigh In

MRK has been the subject of a number of recent analyst reports. Morgan Stanley lowered their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their target price for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. Citigroup initiated coverage on Merck & Co., Inc. in a research report on Monday, October 13th. They set a “neutral” rating and a $95.00 price objective for the company. Finally, Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Hold” and a consensus price target of $104.33.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.